文献速递前列腺癌

雄激素受体剪接变异体7预测转移性激素敏感性前列腺癌ADT应答缩短

Androgen Receptor Splice Variant 7 Predicts Shorter Response in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Deprivation Therapy.
PubMed 文献 · Eur Urol · 2021-02-10

这项多中心前瞻性队列研究纳入310例起始ADT的mHSPC患者,用免疫组化检测活检组织AR-V7蛋白。21%为AR-V7阳性,其PFS和OS显著更短,多因素分析中AR-V7是更短PFS的独立预测因素。

要点

  • AR-V7阳性mHSPC患者接受ADT后PFS和OS显著更短。
  • AR-V7是mHSPC患者ADT后更短PFS的独立预测因素。
  • 治疗前活检组织免疫组化检测AR-V7或有助于预后分层。

核心结论

  • 原发癌组织中AR-V7表达与接受ADT的mHSPC患者不良预后相关。

研究设计与样本

  • 多中心前瞻性队列研究纳入310例起始ADT的mHSPC患者。
  • 用标准免疫组化染色评估ADT开始前活检组织的AR-V7蛋白表达。

主要发现

  • 未确认死亡患者的中位随访为25个月(四分位距10-30)。
  • AR-V7阳性较阴性患者PFS显著更短(HR 47.39,95%CI 25.83-86.94)。
  • AR-V7阳性较阴性患者OS显著更短(HR 3.57,95%CI 1.46-8.72)。
  • 多因素分析中AR-V7是更短PFS的独立预测因素(HR 7.61,95%CI 5.24-11.06)。

临床怎么用

  • 对拟起始ADT的mHSPC患者,可考虑检测原发癌组织AR-V7蛋白以辅助预后判断。

局限性

  • 局限性包括样本量和随访时间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Whether AR-V7 expression can predict the response in patients with metastatic hormone-sensitive prostate cancer (mHSPC) who receive androgen deprivation therapy (ADT) remains to be explored. OBJECTIVE: To evaluate the predictive value of AR-V7 expression in the prognosis of mHSPC patients receiving ADT. DESIGN, SETTING, AND PARTICIPANTS: In this multicenter prospective cohort study, 310 mHSPC patients commencing ADT were enrolled. Standard immunohistochemical staining was used to assess AR-V7 protein expression in biopsy tissues collected before initiation of ADT. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Kaplan-Meier survival estimates and Cox regression analyses were used to evaluate associations of AR-V7 status (positive vs negative) with progression-free survival (PFS) and overall survival (OS). RESULTS AND LIMITATIONS: Sixty-four (21%) patients were AR-V7-positive and 246 (79%) patients were AR-V7-negative. The median follow-up for patients not confirmed dead was 25 mo (interquartile range 10-30). Compared to AR-V7-negative patients, AR-V7-positive patients had significantly shorter PFS (hazard ratio [HR] 47.39, 95% confidence interval [CI] 25.83-86.94) and OS (HR 3.57, 95% CI 1.46-8.72). In multivariable analysis, AR-V7 was an independent predictive factor (HR 7.61, 95% CI 5.24-11.06) for shorter PFS. Limitations include the sample size and follow-up period. CONCLUSIONS: AR-V7 expression in primary cancer tissue is correlated with poor prognosis for mHSPC patients receiving ADT. PATIENT SUMMARY: In this study of men with metastatic hormone-sensitive prostate cancer, AR-V7 protein expression in primary cancer tissue was associated with poor outcomes on androgen deprivation therapy.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Li H, Zhang Y, Li D, et al. Androgen Receptor Splice Variant 7 Predicts Shorter Response in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Deprivation Therapy. Eur Urol. 2021. PMID: 33579577. doi:10.1016/j.eururo.2021.01.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。